600285 羚锐制药
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入909,04715.27%3,311,4733,001,8622,693,5112,331,577
减:营业总成本696,49811.84%2,683,3042,584,4172,296,6341,997,801
    其中:营业成本221,83219.87%884,387832,114692,993538,403
               财务费用(8,021)37.83%(35,120)(26,588)(10,334)(15,290)
               资产减值损失(4)-88.31%(2,873)(171)(8,775)(32,028)
公允价值变动收益7331,642.96%1215,92646(52)
投资收益6,85665.39%20,15458,65530,55541,208
    其中:对联营企业和合营企业的投资收益(4)-110.35%(385)43,35018,52233,230
营业利润220,82629.42%656,307517,121435,012367,092
利润总额220,82029.93%653,044517,035413,351364,201
减:所得税费用30,49218.31%84,92851,73050,85239,819
净利润190,32932.01%568,116465,305362,500324,382
减:非控股权益(50)-24.33%60957(1,107)
股东净利润190,37931.98%568,109465,305361,543325,489

市场价值指针
每股收益 (元) *0.34030.77%1.0120.8360.6500.573
每股派息 (元) *----0.8000.6000.5000.400
每股净资产 (元) *5.1738.77%4.9214.4954.0144.073
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容